



## **BIO-Europe® 2017: iTeos CEO on making noise in busy IO field**

January 18, 2018

Michel Detheux, CEO of iTeos Therapeutics, chats with Mike Ward, global director of content for Informa Pharma Insights, about the emerging company's pipeline of immuno-oncology therapeutics. Over the last two years, in Europe alone, around 50 IO startups have been created—but the challenge now for businesses in this R&D space is how to differentiate from the competition. Based in Belgium, iTeos was founded in 2012; Detheux talks about how the company, which has an IDO1 inhibitor in Phase I that is partnered with US pharma giant Pfizer, is getting attention in this crowded market.